Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Krystal Biotech's share price for the quarter that ended in Dec. 2023 was $124.06. Krystal Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 28.24 Mil. Therefore, Krystal Biotech's market cap for the quarter that ended in Dec. 2023 was $3,503.05 Mil.
Krystal Biotech's quarterly market cap
declined
from Jun. 2023 ($3,284.25 Mil) to Sep. 2023 ($3,270.59 Mil) but then
increased
from Sep. 2023 ($3,270.59 Mil) to Dec. 2023 ($3,503.05 Mil).
Krystal Biotech's annual market cap
increased
from Dec. 2021 ($1,763.30 Mil) to Dec. 2022 ($2,041.00 Mil) and
increased
from Dec. 2022 ($2,041.00 Mil) to Dec. 2023 ($3,503.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Krystal Biotech's Enterprise Value for Today is $3,980.93 Mil.
Krystal Biotech Market Cap Historical Data
The historical data trend for Krystal Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Krystal Biotech's Market Cap
For the Biotechnology subindustry, Krystal Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Market Cap falls into.
Krystal Biotech Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Krystal Biotech's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (NAS:KRYS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Krystal Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Krystal Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Krystal Biotech (Krystal Biotech) Business Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRYS has been successfully added to your 